R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation
RIDA®GENE Flu & SARS-CoV-2 test is a multiplex real-time RT-PCR for the direct qualitative detection and differentiation of Flu A/Flu B and coronavirus (SARS-CoV-2) RNA in human nasal/throat swabs from persons with signs and symptoms of respiratory infection. It is intended for professional use for example in hospital laboratories, reference laboratories, private laboratories, or public laboratories. The RIDA®GENE Flu & SARS-CoV-2 multiplex test targets the M gene/NP1 gene of the virus for Influenza A/B and the E gene and RdRpgene in all currently known variants and mutations of the COVID 19 virus.
Only validated products, or products on the temporary protocol, can be sold in the UK after 31 October 2021. Jason Baggaley, Sales Manager of R-Biopharm for Great Britain, commented: “We are proud that our RIDA®GENE Flu & SARS-CoV-2 test was approved and added to the CTDA register and our customers will continue to be able to distinguish between the flu and an infection with the Corona virus.“
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com
https://r-biopharm.com/news-press
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany
Tel.: 0 61 51 - 81 02-538
Mobile: 0 160 - 55 273 60
Fax: 0 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
Images
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
New management for the EUTOP Group22.4.2024 10:51:42 CEST | Press release
Stefan Mappus is the new Managing Director of the EUTOP Group. Together with long-standing Managing Director Christian Schaufler, he will manage the fortunes of the Group from now on. Stefan Mappus is responsible for EUTOP's client business as a member of the management board and thus brings his wealth of experience in politics, administration and business directly to the benefit of EUTOP's clients.
Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform Plans to use innovative Bosch BioMEMS technology in PCR tests for multiresistant bacteria18.4.2024 10:15:00 CEST | Press release
Bosch and R-Biopharm are jointly investing 150 million euros in the development of new PCR tests and in marketing. PCR test for multiresistant gram-negative (MRGN) bacteria to be developed using novel BioMEMS technology. BioMEMS chips permit simultaneous testing of up to 250 genetic characteristics – in some cases, in less than 15 minutes. Darmstadt, Gerlingen, and Waiblingen, Germany – The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform. The two companies will invest a total of 150 million euros by the end of the decade. Within their strategic development and distribution partnership, the partners intend t
Elatec Brings Employee Badge for Apple Wallet to Users17.4.2024 08:45:03 CEST | Press release
Munich, April 17, 2024 – Elatec today announced it is bringing employee badge in Apple Wallet to its customers, enabling an organization’s employees or tenants to unlock access to locations and devices with a simple tap of their iPhone or Apple Watch. Powered by Elatec’s Mobile Credential Manager software, which works hand-in-hand with Elatec’s universal RFID readers, this brings together the world’s most powerful and versatile readers with the best mobile access system available. Employee badge in Apple Wallet helps deliver a convenient and contactless experience for users. Once enabled, employee badge in Apple Wallet allows users to seamlessly and securely add their employee badge to Apple Wallet, and hold their iPhone or Apple Watch near an NFC reader to unlock office doors, turnstiles, elevators and key card-protected amenity spaces — eliminating the need to open an app or present a traditional, plastic access key. With Express Mode, employees do not need to unlock their device to
National Research Center for Applied Cybersecurity ATHENE: Severe Vulnerabilities Discovered in Software to Protect Internet Routing12.4.2024 08:49:14 CEST | Press release
A research team from the National Research Center for Applied Cybersecurity ATHENE led by Prof. Dr. Haya Schulmann has uncovered 18 vulnerabilities in crucial software components of Resource Public Key Infrastructure (RPKI). RPKI is an Internet standard meant to protect Internet traffic from being hijacked by hackers. By now, all affected vendors provided patches for their products. The vulnerabilities could have had devastating consequences: Internet hijacks have already been exploited, e.g., for phishing passwords and other sensitive information, tricking certificate authorities into issuing fraudulent Web certificates, stealing cryptocurrency, distributing malware, and poisoning caches of DNS servers.
Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment10.4.2024 11:00:00 CEST | Press release
The launch in Germany through its step-down subsidiary betapharm marks Dr. Reddy's entry into digital therapeutics in Europe. Nerivio® is the first REN (wearable, FDA-cleared, and CE-marked for acute and/or prevention migraine (with or without aura) treatment for adults and adolescents (≥ 12 years). Nerivio® is worn on the upper arm during treatment and controlled by a smartphone app, making it comfortable and portable. Starting with Germany, followed by Spain and the UK, Dr. Reddy's plans to further increase access to Nerivio® in European countries.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom